［1］CHEN N，FANG W，ZHAN J，et al.Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-Driven NSCLC：Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation［J］.Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer，2015，10(6)：910-923.
［2］CASTRO F，CARDOSO AP，GONCALVES RM，et al.Interferon-gamma at the crossroads of tumor immune surveillance or evasion［J］.Frontiers in Immunology，2018，9(2)：847.
［3］WANG LQ.CAR-T and immune cell tumor therapy ［J］.Chinese Journal of Cell Biology,2019,41(4):540-548.
［4］HSU J，HODGINS JJ，MARATHE M，et al.Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade［J］.J Clin Invest，2018，128(10)：4654-4668.
［5］ALBERSHARDT TC，PARSONS AJ，REEVES RS，et al.Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine［J］.Vaccine，2020,38(17):3369-3377.
［6］CAI J，WANG D，ZHANG G，et al.The role of PD-1/PD-L1 axis in Treg development and function：Implications for cancer immunotherapy［J］.OncoTargets and Therapy，2019，12：8437.
［7］HAN Y，LIU D，LI L.PD-1/PD-L1 pathway：Current researches in cancer［J］.American Journal of Cancer Research，2020，10(3)：727.
［8］YI M，ZHENG X，NIU M，et al.Combination strategies with PD-1/PD-L1 blockade：current advances and future directions［J］.Molecular Cancer，2022,21(1)：1-27.
［9］GUO HF，DAY ORCHID，CUI JZ.Advances in combined treatment of immune checkpoint inhibitors for lung cancer ［J］.Chinese Journal of Lung Cancer,2020,23(2)：101.
［10］TEO MY，SEIER K，OSTROVNAYA I，et al.Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers［J］.Journal of Clinical Oncology，2018，36(17)：1685.
［11］RIZZO A，RICCI AD.Biomarkers for breast cancer immunotherapy：PD-L1，TILs，and beyond［J］.Expert Opin Investig Drugs,2022,31(6):549-555.
［12］KAGABU M，NAGASAWA T，FUKAGAWA D，et al.Immunotherapy for uterine cervical cancer［J］.Healthcare(Basel)，2019，7(3)：108.
［13］CHAN KL，GOMEZ J，CARDINEZ C，et al.Inhibition of the CtBP complex and FBXO11 enhances MHC class Ⅱ expression and anti-cancer immune responses［J］.Cancer Cell,2022,40(10):1190-1206.
［14］STUTVOET TS，KOL A，DE VRIES EGE，et al.MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells［J］.The Journal of Pathology，2019，249(1)：52-64.
［15］RECK M，RODRIGUEZ-ABREU D，ROBINSON AG，et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer［J］.N Engl J Med，2016，375：1823-1833.
［16］CHO J，AHN S，YOO K H，et al.Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients：Correlative analysis with PD-L1 immunohistochemistry［J］.Investigational New Drugs，2016，34：677-684.
［17］SAHIN IH，AKCE M，ALESE O，et al.Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms［J］.British Journal of Cancer，2019,121(10)：809-818.
［18］YOSHINO T，PENTHEROUDAKIS G，MISHIMA S，et al.JSCO-ESMO-ASCO-JSMO-TOS：International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions［J］.Annals of Oncology，2020，31(7)：861-872.
［19］OVERMAN MJ，KOPETZ S，MCDERMOTT RS，et al.Nivolumab±ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H)：CheckMate-142 interim results［J］.J Clin Onco，2016，34(15):3501.
［20］LE DT，URAM JN，WANG H，et al.PD-1 blockade in tumors with mismatch-repair deficiency［J］.New England Journal of Medicine，2015，372(26)：2509-2520.
［21］SA HUANLAN，MARKWAY，GAO Y，et al.Predictive value of tumor mutation load on immunotherapy of lung cancer ［J］.Chinese Journal of Lung Cancer,2019,22(6)：380.
［22］PAZ-ARES L，CIULEANU T E，COBO M，et al.98O First-line nivolumab (NIVO)+ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC)：Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA［J］.Journal of Thoracic Oncology，2021，16(4)：S750-S751.
［23］GOODMAN AM，KATO S，BAZHENOVA L，et al.Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers［J］.Molecular Cancer Therapeutics，2017，16(11)：2598-2608.
［24］BRAHMER JR，LEE JS，CIULEANU TE，et al.Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227［J］.J Clin Oncol,2023,41(6):1200-1212.
［25］YARCHOAN M ,HOPKINS A,JAFFEE EM.Tumor mutational burden and response rate to PD-1 inhibition［J］.N Engl J Med，2017，377(25)：2500-2501.
［26］GRANDAL B，EVREVIN C，LAAS E，et al.Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs)，response to treatment，and prognosis in breast cancer patients treated with neoadjuvant chemotherapy［J］.Cancers，2020，12(12)：3681.
［27］HERBST RS，SORIA JC，KOWANETZ M，et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients［J］.Nature,2014,515(7528):563.
［28］URYVAEV A,PASSHAK M,HERSHKOVITS D,et al.The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma［J］.Med Oncol，2018，35(3)：25.
［29］HAO J，YU H，ZHANG T，et al.Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer：A systematic review and Meta-analysis［J］.Therapeutic Advances in Medical Oncology，2020,12：1-14.
［30］TANIZAKI J，HARATANI K，HAYASHI H，et al.Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab［J］.Journal of Thoracic Oncology，2018，13(1)：97-105.
［31］MEZQUITA L，AUCLIN E，FERRARA R，et al.Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer［J］.JAMA Oncology，2018，4(3)：351-357.
［32］SOYANO AE，DHOLARIA B，MARIN-ACEVEDO JA，et al.Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies［J］.J Immunother Cancer,2018，6(1):129.
［33］SAKAGUCHI S，MIKAMI N，WING JB，et al.Regulatory T cells and human disease［J］.Annual Review of Immunology，2020，38（2）：541-566.
［34］SCHOONDERWOERD MJA，KOOPS MFM，ANGELA RA，et al.Targeting endoglin expressing regulatory T cells in the tumor microenvironment enhances the effect of PD1 checkpoint inhibitor immunotherapy［J］.Clinical Cancer Research，2020，14(26)：3831-3842.
［35］NI X，TAO J，BARBI J，et al.YAP is essential for Treg-mediated suppression of antitumor immunity［J］.Cancer Discov，2018，8(8)：1026-1043.
［36］BENCI JL，JOHNSON L R，CHOA R，et al.Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade［J］.Cell，2019，178(4)：933-948.
［37］MOON JW，KONG SK，KIM BS，et al.IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma［J］.Scientific reports，2017，7(1)：1-13.
［38］ZHANG M，HUANG L，DING G，et al.Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer［J］.Journal for Immunotherapy of Cancer，2020，8(1)：e000308.
［39］SUN L，WANG Q，CHEN B，et al.Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis［J］.Cell Death & Disease，2018，9(9)：1-11.
［40］DOMINGUES B，LOPES JM，SOARES P，et al.Melanoma treatment in review［J］.ImmunoTargets and Therapy，2018，7（1）：35.
［41］SANMAMED MF，PEREZ-GRACIA JL，SCHALPER KA，et al.Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients［J］.Annals of Oncology，2017，28(8)：1988-1995.
［42］KLEPSCH V，HERMANN-KLEITER N，BAIER G.Beyond CTLA-4 and PD-1：Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy［J］.Immunology Letters，2016，178(1)：31-36.
［43］KLAPPER L，RIBBAT-IDEL J，KUPPLER P，et al.NR2F6 as a prognostic biomarker in HNSCC［J］.International Journal of Molecular Sciences，2020，21(15)：5527.
［44］CHEN DS，MELLMAN I.Elements of cancer immunity and the cancer-immune set point［J］.Nature，2017，541(7637)：321-330.
［45］CHANG L，CHENG Q，MA Y，et al.Prognostic effect of the controlling nutritional status score in patients with esophageal cancer treated with immune checkpoint inhibitor［J］.J Immunother，2022,45(9):415-422.